II. Background

  1. Planned release 2018 in U.S.

III. Mechanism

  1. Antidote for Eliquis (Apixaban) or Xarelto (Rivaroxaban), but not other Factor Xa Inhibitors
  2. Andexxa is a Inactivated Recombinant Factor Xa decoy protein that binds Factor Xa Inhibitors

IV. Efficacy

  1. Limits progression of bleeding within 12 hours of dose (onset as early as 1 hour)
  2. Ineffective in the 25% of patients who have low anti-Factor Xa Inhibitor

V. Adverse Effects

  1. Expensive: $25,000 to 50,000 per patient
  2. Risk of Hypercoagulability complications (CVA, VTE)

VI. References

Images: Related links to external sites (from Bing)

Related Studies